Corbus Pharmaceuticals Reports 3rd Quarter 2024 Financial Results and Provides a Corporate Update November 7, 2024
Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference October 29, 2024
Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701) October 16, 2024
Corbus Pharmaceuticals to Participate in the BMO Capital Markets’ Oncology Summit September 26, 2024
Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung August 20, 2024
Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update August 6, 2024
SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024 June 1, 2024
Corbus Pharmaceuticals to Present at the 45th Annual Goldman Sachs Global Healthcare Conference May 30, 2024
Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting May 23, 2024
Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference May 9, 2024
Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update May 7, 2024
Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting April 24, 2024
Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC April 2, 2024
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update March 12, 2024
Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit March 6, 2024
Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference February 6, 2024
Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares February 2, 2024
